Tags

Type your tag names separated by a space and hit enter

The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease.
Int J Geriatr Psychiatry. 2000 Jul; 15(7):644-9.IJ

Abstract

The concurrent validity of the Hamilton Rating Scale for Depression (HAMD-17) and the Montgomery-Asberg Depression Rating Scale (MADRS) against the DSM-IV diagnosis 'depressive disorder' was assessed in patients with Parkinson's disease (PD). Sixty-three non-demented Parkinson's Disease (PD) patients who attended the outpatient department of an academic hospital were diagnosed according to a standardised research protocol. This protocol consisted of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) to establish the presence or absence of 'depressive disorder' according to the DSM-IV criteria, as well as the HAMD-17 and the MADRS. Receiver Operating Characteristics curves (ROC curves) were obtained and the positive and negative predictive values (PPV, NPV) were calculated for different cut-off scores. Maximum discrimination between depressed and non-depressed patients was reached at a cut-off score of 13/14 for the HAMD-17, and at 14/15 for the MADRS. At lower cut-offs, like 11/12 for the HAMD-17 and 14/15 for the MADRS, the high sensitivity and NPV make these scales good screening instruments. At higher cut-offs, such as 16/17 for the HAMD-17 and 17/18 for the MADRS, the high specificity and PPV make these instruments good diagnostic instruments. The diagnostics performance of the HAMD-17 is slightly better than that of the MADRS. This study shows that it is justified to use the HAMD-17 and the MADRS to measure depressive symptoms in both non-depressed and depressed PD patients, to diagnose depressive disorder in PD, and to dichotomize patient samples into depressed and non-depressed groups.

Authors+Show Affiliations

Department of Psychiatry, Maastricht University Hospital, The Netherlands. a.leentjens@np.unimaas.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

10918346

Citation

Leentjens, A F., et al. "The Validity of the Hamilton and Montgomery-Asberg Depression Rating Scales as Screening and Diagnostic Tools for Depression in Parkinson's Disease." International Journal of Geriatric Psychiatry, vol. 15, no. 7, 2000, pp. 644-9.
Leentjens AF, Verhey FR, Lousberg R, et al. The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry. 2000;15(7):644-9.
Leentjens, A. F., Verhey, F. R., Lousberg, R., Spitsbergen, H., & Wilmink, F. W. (2000). The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. International Journal of Geriatric Psychiatry, 15(7), 644-9.
Leentjens AF, et al. The Validity of the Hamilton and Montgomery-Asberg Depression Rating Scales as Screening and Diagnostic Tools for Depression in Parkinson's Disease. Int J Geriatr Psychiatry. 2000;15(7):644-9. PubMed PMID: 10918346.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. AU - Leentjens,A F, AU - Verhey,F R, AU - Lousberg,R, AU - Spitsbergen,H, AU - Wilmink,F W, PY - 2000/8/5/pubmed PY - 2000/9/9/medline PY - 2000/8/5/entrez SP - 644 EP - 9 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 15 IS - 7 N2 - The concurrent validity of the Hamilton Rating Scale for Depression (HAMD-17) and the Montgomery-Asberg Depression Rating Scale (MADRS) against the DSM-IV diagnosis 'depressive disorder' was assessed in patients with Parkinson's disease (PD). Sixty-three non-demented Parkinson's Disease (PD) patients who attended the outpatient department of an academic hospital were diagnosed according to a standardised research protocol. This protocol consisted of the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) to establish the presence or absence of 'depressive disorder' according to the DSM-IV criteria, as well as the HAMD-17 and the MADRS. Receiver Operating Characteristics curves (ROC curves) were obtained and the positive and negative predictive values (PPV, NPV) were calculated for different cut-off scores. Maximum discrimination between depressed and non-depressed patients was reached at a cut-off score of 13/14 for the HAMD-17, and at 14/15 for the MADRS. At lower cut-offs, like 11/12 for the HAMD-17 and 14/15 for the MADRS, the high sensitivity and NPV make these scales good screening instruments. At higher cut-offs, such as 16/17 for the HAMD-17 and 17/18 for the MADRS, the high specificity and PPV make these instruments good diagnostic instruments. The diagnostics performance of the HAMD-17 is slightly better than that of the MADRS. This study shows that it is justified to use the HAMD-17 and the MADRS to measure depressive symptoms in both non-depressed and depressed PD patients, to diagnose depressive disorder in PD, and to dichotomize patient samples into depressed and non-depressed groups. SN - 0885-6230 UR - https://www.unboundmedicine.com/medline/citation/10918346/The_validity_of_the_Hamilton_and_Montgomery_Asberg_depression_rating_scales_as_screening_and_diagnostic_tools_for_depression_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/1099-1166(200007)15:7<644::aid-gps167>3.0.co;2-l DB - PRIME DP - Unbound Medicine ER -